Table A2.
NMA treatment effect/study IDs | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
---|---|---|---|---|---|---|---|---|---|---|---|
Mixed estimates | |||||||||||
ACE: BBlocker | 10.3307 | 8.8137 | 0.014 | 3.5622 | 4.3208 | 24.5731 | 1.5633 | 2.7752 | 0.1198 | 1.633 | 3.6652 |
ACE: CCB | 8.5763 | 22.566 | 0.015 | 4.4111 | 4.3575 | 7.678 | 1.5232 | 3.4642 | 0.1354 | 5.06 | 0.4334 |
ACE: Diuretic | 2.966 | 28.1532 | 0.1067 | 21.3995 | 0.4694 | 4.8986 | 0.2048 | 4.3415 | 1.9589 | 0.51 | 4.8583 |
ACE: Placebo | 1.9547 | 5.9190 | 0.018 | 3.6018 | 0.2729 | 2.9909 | 1.992 | 22.5414 | 1.396 | 5.13 | 0.2629 |
ARB: BBlocker | 2.0761 | 0.1095 | 0.275 | 0.0264 | 5.233 | 3.1626 | 6.3872 | 2.0749 | 0.4382 | 1.373 | 1.7846 |
ARB: CCB | 1.4515 | 3.4458 | 0.28 | 0.2076 | 4.0937 | 0.0847 | 6.8536 | 1.6732 | 0.4578 | 4.785 | 0.0768 |
ARB: Diuretic | 0.7138 | 12.4406 | 0.94 | 4.3368 | 0.1391 | 1.4247 | 9.6542 | 1.6096 | 2.3744 | 0.245 | 5.9383 |
ARB: Placebo | 1.1829 | 2.6439 | 0.27 | 0.173 | 0.0511 | 2.2164 | 29.3029 | 2.785 | 0.7071 | 5.405 | 0.9829 |
BBlocker: CCB | 6.1387 | 5.253 | 0.0033 | 0.3209 | 19.189 | 4.1994 | 0.0411 | 0.3159 | 0.0146 | 2.197 | 2.7772 |
BBlocker: Diuretic | 3.4497 | 14.3396 | 0.195 | 6.6748 | 5.26 | 6.944 | 1.3269 | 0.3335 | 1.2104 | 1.127 | 17.0469 |
BBlocker: Placebo | 3.9049 | 2.5437 | 0.0025 | 0.1626 | 4.412 | 8.1344 | 5.0268 | 6.7234 | 1.5011 | 7.585 | 4.0594 |
CCB: Diuretic | 2.4724 | 29.5536 | 0.19 | 5.6663 | 3.405 | 1.4981 | 1.2703 | 0.1075 | 1.3754 | 4.295 | 5.7463 |
CCB: Placebo | 2.9389 | 9.2002 | 0.005 | 0.4033 | 2.9195 | 2.3524 | 5.0386 | 5.8199 | 1.701 | 20.38 | 0.6771 |
Diuretic: Placebo | 0.4631 | 11.8137 | 0.2 | 7.0979 | 0.0795 | 0.7936 | 2.4089 | 6.1784 | 6.8192 | 5.895 | 3.4892 |
Indirect estimates | |||||||||||
ACE: ARB | 4.1417 | 8.194 | 0.31 | 2.5678 | 0.2111 | 7.4768 | 11.0341 | 6.9973 | 0.2685 | 0.135 | 0.5577 |
NMA treatment effect/study IDs | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 |
---|---|---|---|---|---|---|---|---|---|---|---|
Mixed estimates | |||||||||||
ACE: BBlocker | 1.7862 | 0.9888 | 4.2769 | 2.673 | 4.0015 | 3.3405 | 2.6568 | 1.1975 | 0.3826 | 17.213 | 0.102 |
ACE: CCB | 2.2297 | 4.1373 | 4.3133 | 0.062 | 0.8908 | 3.3688 | 3.3164 | 1.1668 | 0.4327 | 19.095 | 2.767 |
ACE: Diuretic | 2.7944 | 5.3117 | 0.4647 | 0.028 | 4.4307 | 0.3629 | 4.1563 | 0.1569 | 6.2576 | 5.8771 | 0.283 |
ACE: Placebo | 14.5088 | 0.1056 | 0.2701 | 1.85 | 3.7802 | 0.211 | 21.5798 | 1.526 | 4.4594 | 3.9696 | 1.65 |
ARB: BBlocker | 1.3355 | 0.0283 | 5.1799 | 34.71 | 3.4897 | 4.0457 | 1.9863 | 4.8928 | 1.4 | 3.5611 | 16.42 |
ARB: CCB | 1.077 | 1.5781 | 4.0521 | 13.19 | 1.0817 | 3.1649 | 1.6018 | 5.2501 | 1.4623 | 3.2522 | 40.87 |
ARB: Diuretic | 1.036 | 7.6843 | 0.1377 | 11.59 | 5.3801 | 0.1076 | 1.541 | 7.3955 | 7.5852 | 1.316 | 16.41 |
ARB: Placebo | 1.7925 | 1.1644 | 0.0506 | 7.640 | 3.3529 | 0.0395 | 2.6662 | 22.4471 | 2.2589 | 2.2608 | 10.61 |
BBlocker: CCB | 0.2033 | 2.3306 | 18.9941 | 4.091 | 2.6689 | 14.8351 | 0.3024 | 0.0314 | 0.0468 | 12.0214 | 4.015 |
BBlocker: Diuretic | 0.2147 | 7.6154 | 5.2066 | 2.688 | 11.2137 | 4.0665 | 0.3193 | 1.0164 | 3.8665 | 5.7249 | 0.15 |
BBlocker: Placebo | 4.3275 | 1.1495 | 4.3672 | 6.785 | 12.1509 | 3.411 | 6.4366 | 3.8507 | 4.7953 | 6.5805 | 2.09 |
CCB: Diuretic | 0.0692 | 20.2684 | 3.3704 | 0.032 | 4.6091 | 2.6324 | 0.1029 | 0.9731 | 4.3937 | 5.4936 | 2.465 |
CCB: Placebo | 3.746 | 4.3218 | 2.8898 | 1.743 | 5.1204 | 2.2571 | 5.5716 | 3.8597 | 5.4339 | 6.4603 | 7.15 |
Diuretic: Placebo | 3.9767 | 4.7994 | 0.0787 | 1.711 | 11.3410 | 0.0615 | 5.9148 | 1.8453 | 21.784 | 0.9058 | 2.343 |
Indirect estimates | |||||||||||
ACE: ARB | 4.5038 | 1.1364 | 0.2089 | 13.29 | 0.5508 | 0.1632 | 6.6988 | 8.4525 | 0.8579 | 8.0201 | 14.21 |
Note: Columns refer to studies and rows refer to NMA relative treatment effects. Entries show how much each study contributes to the estimation of NMA relative treatment effects. The table can be downloaded as a .csv file by clicking on “Download per study contribution matrix” in “Configuration.”
Abbreviations: ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers; BBlocker, Beta Blocker; CCB, calcium‐channel blocker.